Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$3.22 USD

3.22
357,505

+0.04 (1.26%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.

Zacks Equity Research

Best Momentum Stocks to Buy for January 6th

by Zacks Equity Research

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

Zacks Equity Research

Best Value Stocks to Buy for January 6th

by Zacks Equity Research

AHT, PBYI and CWD made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2024.

Zacks Equity Research

All You Need to Know About Puma Biotech (PBYI) Rating Upgrade to Strong Buy

by Zacks Equity Research

Puma Biotech (PBYI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

by Zacks Equity Research

Sales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise.

Zacks Equity Research

Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Best Momentum Stocks to Buy for December 24th

by Zacks Equity Research

PBYI, DDS and NJR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 24, 2024.

Zacks Equity Research

New Strong Buy Stocks for December 24th

by Zacks Equity Research

FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.

Zacks Equity Research

Best Value Stocks to Buy for December 24th

by Zacks Equity Research

PBYI, DDS and PINC made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 24, 2024.

Zacks Equity Research

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

by Zacks Equity Research

Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.

Zacks Equity Research

PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up

by Zacks Equity Research

Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. Stock rallies.

Zacks Equity Research

Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 28.57% and 12.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected

by Zacks Equity Research

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.

Zacks Equity Research

Zacks.com featured highlights Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity

by Zacks Equity Research

Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity are part of the Zacks Screen of the Week article.

Zacks Equity Research

Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 50% and 7.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Vaishali Doshi headshot

Bet on These 4 Top-Performing Liquid Stocks for Solid Gains

by Vaishali Doshi

Here are four top-performing liquid stocks, Abercrombie & Fitch (ANF), Puma Biotechnology (PBYI), Spotify (SPOT) and Oddity Tech (ODD), which investors can add to their portfolio to augment returns

Zacks Equity Research

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.

Zacks Equity Research

Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.

Zacks Equity Research

Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat

by Zacks Equity Research

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.

Zacks Equity Research

Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 68.75% and 5.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?

by Zacks Equity Research

On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.